Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Aug;62(8):1088-1093.
doi: 10.1111/ijd.16676. Epub 2023 Apr 29.

JAK inhibitors: a novel, safe, and efficacious therapy for pyoderma gangrenosum

Luiz G M Castro  1   2   3
Affiliations
Case Reports

JAK inhibitors: a novel, safe, and efficacious therapy for pyoderma gangrenosum

Luiz G M Castro. Int J Dermatol. 2023 Aug.

Abstract

Background: Pyoderma gangrenosum currently lacks standardized therapy. New safer and more efficacious therapies are welcome.

Aims: To present two new PG cases treated with JAK inhibitors, adding to the small existing experience METHODS & METHODS: Two case reports of PG patients successfully treated with tofacitinib and baricitinib.

Results: Both patients were cured and presented no relapse. Patient # 1 used baricitinib 2 mg bid for 39 days while patient # 2 was treated with tofacitinib 5 mg bid for 120 days. No adverse reactions were seen.

Discussion: The increasing usage of JAKi to treat inflammatory diseases had a positive reflex on PG therapy. Fifteen PG cases treated with these drugs had been found in literature and the two new cases here described add to the limited existing experience.

Conclusion: This is a novel use of tofacitinib and baricitinib beyond the approved indications. JAKi are a welcome addition to our options to manage patients with PG.

PubMed Disclaimer

References

    1. Alves de Medeiros AK, Speeckaert R, Desmet E, Van Gele M, De Schepper S, Lambert J. JAK3 as an emerging target for topical treatment of inflammatory skin diseases. PLoS One. 2016;11(10):e0164080.
    1. Scheinberg M, Machado LA, Castro LG, Ferreira SB, Michalany N. Successful treatment of ulcerated pyoderma gangrenosum with baricitinib, a novel JAK inhibitor. J Transl Autoimmun. 2021;4:100099. https://doi.org/10.1016/j.jtauto.2021.100099
    1. Palanivel JA, Macbeth AE, Levell NJ. Pyoderma gangrenosum in association with Janus kinase 2 (JAK2V617F) mutation. Clin Exp Dermatol. 2013;38(1):44-6. https://doi.org/10.1111/j.1365-2230.2012.04375.x
    1. Shanmugam VK, McNish S, Shara N, Hubley KJ, Kallakury B, Dunning DM, et al. Chronic leg ulceration associated with polycythemia vera responding to ruxolitinib (Jakafi®). J Foot Ankle Surg. 2013;52(6):781-5. https://doi.org/10.1053/j.jfas.2013.07.003
    1. Nasifoglu S, Heinrich B, Welzel J. Successful therapy for pyoderma gangrenosum with a Janus kinase 2 inhibitor. Br J Dermatol. 2018;179(2):504-5. https://doi.org/10.1111/bjd.16468

Publication types

MeSH terms

LinkOut - more resources